Mind Medicine (MindMed) Inc. (MNMD) News
Filter MNMD News Items
MNMD News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
MNMD News Highlights
- For MNMD, its 30 day story count is now at 2.
- Over the past 3 days, the trend for MNMD's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- LOAN, MET and NEO are the most mentioned tickers in articles about MNMD.
Latest MNMD News From Around the Web
Below are the latest news stories about MIND MEDICINE (MINDMED) INC that investors may wish to consider to help them evaluate MNMD as an investment opportunity.
Weekly Roundup on the Cannabis Sector & Psychedelic SectorKey Takeaways; Cannabis Sector • Canopy Growth implemented share consolidation to meet Nasdaq listing standards. • Curaleaf successfully listed on the Toronto Stock Exchange. • Safe Harbor Financial boosted social equity in Connecticut with a $1.17m loan to Higher Collective. Key Takeaways; Psychedelic Sector • Awakn achieved significant regulatory milestone and closed financing tranche as […] |
MindMed Announces Positive Topline Results from Phase 2b Trial of MM-120 in Generalized Anxiety DisorderNEW YORK, December 14, 2023--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced positive topline results from its Phase 2b clinical trial of MM-120 (lysergide d-tartrate) in generalized anxiety disorder (GAD). The trial met its primary endpoint, with MM-120 demonstrating statistically significant and clinically meaningful dose-depend |
GH Research Drags Down Psychedelic Drug Stocks Index By 7%The 5 constituents in the Psychedelic Drug Stocks Index continue to exhibit extreme volatility week after week. |
MindMed Reports Third Quarter 2023 Financial Results and Business HighlightsNEW YORK, November 02, 2023--MindMed today reported its financial results for the quarter ended September 30, 2023. |
MindMed to Host Conference Call and Webcast to Discuss Third Quarter 2023 Financial Results and Provide Business UpdateNEW YORK, October 26, 2023--MindMed plans to host a conference call on Thursday, November 2, 2023, at 4:30 p.m. ET. |
MindMed Completes Enrollment of Phase 2a Trial of MM-120 in Adults with Attention-Deficit/Hyperactivity Disorder (ADHD)NEW YORK, October 24, 2023--Enrollment completed for MMED007, the Phase 2a study evaluating repeated low-dose administration of MM-120 for the treatment of adults with ADHD. |
3 Pharma Stocks to Dump Before the Damage Is DoneThere's never a shortage of pharma stocks to sell due to the nature of the sector, especially when compounded by current fears. |
MindMed to Present Data on the Preclinical Activity of MM-402 at the 36th Annual European College of Neuropsychopharmacology (ECNP) CongressNEW YORK, October 03, 2023--MindMed will present preclinical data for MM-402 in a model for autism spectrum disorder. |
MindMed to Participate in the TD Cowen 3rd Annual Novel Mechanisms in Neuropsychiatry SummitNEW YORK, September 14, 2023--MindMed will participate in a panel at the TD Cowen 3rd Annual Novel Mechanisms in Neuropsychiatry Summit. |
MindMed Completes Enrollment of Phase 2b Trial of MM-120 in Generalized Anxiety Disorder (GAD)NEW YORK, September 12, 2023--MindMed has completed enrollment and dosing in Study MMED008, the Phase 2b study evaluating MM-120 (lysergide D-tartrate) for the treatment of GAD. |